Iodex goes to SmithKline Beecham consumer Healthcare
Iodex is the market leader in the pain-balm segment, with a market share of 70 per cent-plus. Iodex faces challenges from local brands like Amrutanjan, Tiger Balm (locally manufactured by Elder Pharma), Zandu Balm and Sensur of Glenmark. //
India (GSK) has decided to transfer...
New Cervical Cancer Vaccine to Be Launched By Glaxo Smithkline
Cervarix, a cervical cancer vaccine produced by Glaxo Smithkline
(Britain's biggest drug manufacturer) is being registered for approval// by the European regulatory authority. If approved, the vaccine would be marketed for commercial use, by the end of next year.
Gardasil, a similar vaccine ...
Cancer Patients Use New Guided Imagery CD to Help Boost Healthy Immune Functioning
... and hundreds of U.S. hospitals, including Mayo, Columbia Presbyterian, the Cleveland Clinic and Bethesda Naval Hospital. Pharmas such as Roche, Glaxo smithkline
and Ortho Biotech have distributed over half a million CDs to Chemotherapy and Radiation patients around the English speaking world, and there are cur...
Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB
...xcellence in 2005. In 2004, IBC Conferences named him Chief Scientific Officer of the Year.
Prior to joining Wyeth, Dr. Ruffolo spent 17 years at smithkline
Beecham (now GSK) and 6 years at Lilly Research Laboratories. During his career, Dr. Ruffolo played a significant role in the discovery and/or develop...
Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
...trategic planning and business development while at Inotek Pharmaceuticals Corp., Exact Sciences Corp., Pathogenesis Corp. (now part of Novartis), and smithkline
Beecham (now part of GlaxoSmithKline).
"I am looking forward to working with Dr. Celniker and the rest of the team that she has assembled as...
Watson Pharmaceuticals Reports Third Quarter 2008 Results
Risperdal(R) is a registered trademark of Johnson & Johnson Corporation. Lamictal(R) is a registered trademark of smithkline
The following table presents Watson's results of operations for the
three and nine months ended September 30, 2008 and 2007:
Smart Balance Announces Marketing Organization Appointment
...ountry's leading manufacturer of composite
decking. Prior to that he held senior leadership roles with Mead
Johnson/Bristol-Myers Squibb, Rite Aid and smithkline
Healthcare. McWilliams has a BA from Westminister College and an MBA from
Harvard Graduate School of Business.
The Company issued t...
Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
...cal Operations Manager for Scherer DDS (a division of RP Scherer) from
1994 to 1999; and various European clinical research positions with Beecham
Beecham and GH Besselaar from 1983-1994. Dr. Clarke holds a
Bachelors of Science in Pharmacology from University of Sunderland and a
PhD in Psychophar...
Memory Pharmaceuticals Appoints Paul Blake to Board of Directors
...esident, Worldwide Medical and Regulatory Operations. He has also served
as Chief Medical Officer for MDS Proteomics, Inc. and as Medical Director
Beecham Pharmaceuticals, where he was responsible for its
worldwide clinical research and development operations. "We are delighted to welcome Paul t...
Healthcare Veteran Richard Findlay Joins Diamond Management & Technology Consultants as Partner
...nagement & Technology
Consultants, Inc. (Nasdaq: DTPI ) announced today that Richard Findlay,
whose experience includes senior executive positions at smithkline
and Abbott Laboratories, has joined the firm as a partner in its healthcare
practice. Findlay has 25 years of experience in both managing and...
SmithKline in Medical Technology
SmithKline in Biological Technology
Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
...utive Team. Dr. Greig originally joined GSK (then smithkline
& French) in 1980 in the Departments of Tumor ...d Human Genome Sciences. In 1996 Dr. Greig joined smithkline
Beecham's European Pharmaceutical Operations as Vi...appointed Managing Director and General Manager of smithkline
Beecham's UK Pharmaceuticals. Following the merge...
Transgenomic, Inc. Announces Appointment of New Board Members
...Drug Free workplace, plc, London, UK; ThauMDx LLC, Santa Barbara, CA; and International Cancer Screening Laboratories, Inc. Mr. McNulty previously ran smithkline
Beecham's Chicago based reference laboratory prior to the company's transition to become Quest Diagnostics.
In making this announcement, Transgen...
Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development
...is Post-Doctoral Fellowship at The Wistar Institute. Previous to joining Axial Biotech, Dr. Macina worked with the molecular diagnostics department at smithkline
Beecham in the discovery and characterization of novel genes differentially expressed in different cancers.
"Dr. Macina's decision to join Axia...
Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
...itions in product development, R&D operations, corporate development and strategy, as well as new product research. Prior to Nektar, he worked at smithkline
Beecham Pharmaceuticals in King of Prussia, PA, where he focused in the areas of pharmaceutical technology formulation sciences and product developmen...
GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
... The solicitation and the tender offer to buy shares of Genelabs is only being made pursuant to the Offer to Purchase and related materials that GSK, smithkline
Beecham Corporation and Gemstone Acquisition Corporation filed with the Securities and Exchange Commission (SEC) on November 12, 2008 and as subsequen...
GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
...dated October 29, 2008 among
Genelabs, Gemstone Acquisition Corporation and smithkline
All other terms and conditions of the tender o...eing made pursuant to the Offer to Purchase
and related materials that GSK, smithkline
Beecham Corporation and Gemstone
Acquisition Corporation filed with the Sec...
GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
...being made pursuant to a previously announced Agreement
and Plan of Merger dated October 29, 2008 among Genelabs, Gemstone Acquisition
Corporation and smithkline
Beecham Corporation, a wholly-owned subsidiary of
All other terms and conditions of the tender offer remain the same,
including the condi...
GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
...es. The tender offer is being made pursuant to a previously announced
Agreement and Plan of Merger dated October 29, 2008 among Genelabs,
Gemstone and smithkline
Beecham Corporation, a wholly-owned subsidiary of
The Genelabs board of directors has unanimously determined that the
tender offer and the merg...
LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease
...mbly unanimously resolved to eliminate the
disease globally as a public health problem. In 1998, two pharmaceutical
companies -- GlaxoSmithKline (then smithkline
Beecham) and Merck & Co.,
Inc. -- partnered with WHO and pledged to donate two of the drugs necessary
for LF elimination (albendazole and Mectizan(R),...
Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
...isease research, biodefense and gene
construction/expression. His previous experience includes assistant
director, Department of Molecular Genetics at smithkline
and French (now
About Lumiphore | Based in Richmond, California, Lumiphore is a
biotechnology leader in the development of proprie...